UnknownNot Applicable

AI-assisted White Light Endoscopy to Identify the Kimura-Takemoto Classification of Atrophic Gastritis

China1,500 participantsStarted 2023-06-01

Plain-language summary

Grading endoscopic atrophy according to the Kimura-Takemoto classification can assess the risk of gastric neoplasia development. However, the false negative rate of chronic atrophic gastritis is high due to the varying diagnostic standardization and diagnostic experience and levels of endoscopists. Therefore, this study aims to develop an AI model to identify the Kimura-Takemoto classification.

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

. patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric;
. disorders who cannot participate in gastroscopy;
. Patients with progressive gastric cancer;
. low quality pictures;
. patients with previous surgical procedures on the stomach or esophageal;
. patients who refuse to sign the informed consent form;

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Accuracy of AI model to diagnose the Kimura-Takemoto classification

Timeframe: 2 years

Sensitivity of AI model to diagnose the Kimura-Takemoto classification

Timeframe: 2 years

Specificity of AI model to diagnose the Kimura-Takemoto classification

Timeframe: 2 years

Trial details

NCT IDNCT05916014

SponsorShandong University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

Contact for this trial

yanqing Li, MD, PHD

0531182169385 liyanqing@sdu.edu.cn

View on ClinicalTrials.gov More Atrophic Gastritis trials

Plain-language summary

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

. patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric;
. disorders who cannot participate in gastroscopy;
. Patients with progressive gastric cancer;
. low quality pictures;
. patients with previous surgical procedures on the stomach or esophageal;
. patients who refuse to sign the informed consent form;